Troy Wichterman Sells 4,151 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 4,151 shares of the business’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $103,775.00. Following the completion of the transaction, the chief financial officer now owns 116,809 shares in the company, valued at approximately $2,920,225. This trade represents a 3.43 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Monday, March 3rd, Troy Wichterman sold 660 shares of BioLife Solutions stock. The stock was sold at an average price of $25.46, for a total value of $16,803.60.
• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total value of $4,219.86.
• On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total value of $26,668.74.

BioLife Solutions Stock Performance

Shares of NASDAQ:BLFS traded down $1.21 during trading on Thursday, hitting $25.06. 278,326 shares of the company traded hands, compared to its average volume of 349,466. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -23.64 and a beta of 2.04. The business’s fifty day moving average is $26.64 and its 200-day moving average is $25.51. BioLife Solutions, Inc. has a one year low of $14.84 and a one year high of $29.55. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.32. The company had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period in the prior year, the company earned ($0.21) earnings per share. As a group, equities analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioLife Solutions

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BLFS. Steward Partners Investment Advisory LLC bought a new position in BioLife Solutions in the 4th quarter worth approximately $26,000. Mark Sheptoff Financial Planning LLC bought a new position in BioLife Solutions in the 3rd quarter worth approximately $28,000. Point72 Asia Singapore Pte. Ltd. bought a new position in BioLife Solutions in the 4th quarter worth approximately $31,000. Quest Partners LLC bought a new position in BioLife Solutions in the 3rd quarter worth approximately $57,000. Finally, 1620 Investment Advisors Inc. grew its holdings in BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 675 shares in the last quarter. 93.24% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BLFS has been the topic of several recent analyst reports. Craig Hallum boosted their price target on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Northland Securities boosted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. KeyCorp boosted their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. HC Wainwright boosted their price objective on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Finally, TD Cowen boosted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to MarketBeat.com, BioLife Solutions has a consensus rating of “Moderate Buy” and a consensus price target of $29.86.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.